STRC Piezoelectric TM Bioelectronic Amplifier

A biocompatible piezoelectric nanofilm (β-phase PVDF-TrFE) deposited on the tectorial-membrane undersurface converts basilar-membrane vibration into local extracellular voltage. That voltage drives prestin electromotility on nearby OHCs directly through field effects on the lateral membrane, bypassing the stereocilia-TM mechanical coupling that STRC is supposed to provide. Result: a synthetic cochlear amplifier that restores Hopf-loop gain regardless of genotype.

Phase 2 finding (2026-04-20): the hypothesis is physics-viable under one specific delivery geometry only — film conformal on the OHC apical membrane at bundle-scale curvature (R ≤ 100 nm). See STRC Piezo Voltage Budget PVDF-TrFE (Phase 1) and STRC Piezo Frequency Response Bundle Mechanics (Phase 2) for details.

Phase 3 finding (2026-04-20): delivery is feasible. A666-functionalised PVDF-TrFE NPs achieve the required coverage at clinical doses — hydrogel-IT 4×10⁸ NPs single or 1×10⁸ × 12 monthly passes 92% of the ≥50 dB audiogram. See STRC Piezo Delivery Feasibility OHC Targeting.

The hidden assumption this breaks

The field assumes the cochlear amplifier is an exclusively biological machine — stereocilia, MET channels, prestin in its native feedback loop. But prestin is a voltage-sensitive motor: in isolated OHC experiments it responds to applied extracellular fields (Santos-Sacchi 1991; Ashmore 2008). If we supply the voltage directly at the right time and place, the stereocilia-MET input becomes replaceable by a synthetic transducer.

Mechanism

1. Sound → basilar membrane vibrates at characteristic frequency per location
2. Vibration deforms the piezo film on TM lower surface (strain ≈ δ/R_curv)
3. Film generates local V_oc (µV–mV depending on d₃₃, film thickness, curvature)
4. Voltage couples across the narrow gap to the OHC lateral wall via AC capacitive divider H(ω) = jωR_mem·C_film / (1 + jωR_mem·(C_film+C_mem))
5. Prestin senses the extracellular field gradient → electromotility
6. OHC length change feeds back into BM motion → Hopf amplification re-engages
7. Stereocilia-TM coupling is no longer on the critical path

Physics summary (detailed numbers in child notes)

Key constants (literature-grounded):

• PVDF-TrFE d₃₃ 25 pC/N, g₃₁ 0.15 V·m/N, Young’s modulus 3 GPa
• OHC specific membrane capacitance 0.9 µF/cm² (C_mem per unit area)
• Prestin activation threshold ~10 mV across membrane
• TM displacement at 60 dB SPL ~1 nm; at 90 dB ~100 nm

Phase 1 voltage budget: macroscopic deposition (R = 1 µm) gives V_wall = 3.6 mV @ 60 dB — below 10 mV prestin threshold. Bundle-scale (R = 100 nm) gives 36 mV — passes comfortably. Details: STRC Piezo Voltage Budget PVDF-TrFE.

Phase 2 frequency response: -3 dB corner at 12.7 kHz; wall-curvature geometry passes the full clinical audiogram at ≥50 dB. Beam-model (film on stereocilia shaft) fails 0/6 frequencies at 60 dB. Strain-model matters by orders of magnitude — details: STRC Piezo Frequency Response Bundle Mechanics.

Candidate materials

Material	d₃₃	Biocompat	Cochlear risk	First-line?
β-PVDF-TrFE	25 pC/N	Well-established (cardiac leads, scaffolds)	Minimal; stable aqueous ionic	Yes
P(VDF-TrFE-CFE) terpolymer	35-40	Similar to PVDF-TrFE	Minor	Upgrade
PLLA (biodegradable)	6-12	FDA for sutures; months lifetime	Low d₃₃ but reversible	Phase-2 iteration
ZnO nanowires	~12	K⁺ dissolution, Zn²⁺ cytotoxic	Fail	No
BaTiO₃ NPs	190	Ba²⁺ cardiotoxic	Fail (pediatric)	No

Design choice: β-PVDF-TrFE baseline; PLLA variant for reversible-therapy pediatric path. Processing: solution-cast from DMF/MEK at <100 nm; anneal at 140 °C for ~90% β-phase content.

Delivery protocol

Goal: get PVDF-TrFE nanoparticles onto OHC apical-membrane-facing surfaces with R ≤ 100 nm effective curvature at ≥60% coverage fraction.

Formulation

Component	Role	Range
PVDF-TrFE nanoparticles (β-phase)	active element	50-200 nm diameter
Self-assembling peptide (RADA-16)	binder / scaffold	1-10 mg/mL
PEG-phospholipid coating	dispersion stabilizer	1-5 mg/mL
Saline carrier	vehicle	150 mM NaCl, pH 7.4
Volume	dose	20-100 µL intratympanic

Nanoparticle functionalisation options:

• Anti-prestin antibody / A666 peptide — OHC-targeted capture (cf. Extracellular Vesicle Delivery Cochlea 2024)
• TMEM145-binding peptide — TM-side anchoring

Administration

1. Intratympanic injection → nanoparticle suspension pools at RWM. Supine tilt 20 min.
2. Low-intensity focused ultrasound 0.5-1 MHz, 100-300 kPa peak, 60 s — sonoporation to drive particles through RWM into perilymph (cf. Liu 2026).
3. Over 4-24 h, gravity + Brownian motion + peptide crosslinking deposit particles. Continuous film not required — disconnected islands each drive a local OHC.

Reversibility & pediatric

• PVDF-TrFE: essentially permanent in vivo; removable only by surgical irrigation.
• PLLA variant: fully biodegradable over 3-12 months. Reversible first-in-child path.
• Intratympanic injection + sonoporation both have pediatric precedent.
• Start with PLLA for first-in-Misha safety: reversible if adverse, observable decay.

Computational proof path

Phases 1, 2, and 3 (delivery feasibility) complete — see child notes. Remaining:

• Phase 3b FEM (FEniCS or COMSOL): 2D axisymmetric cochlear cross-section at mid-turn (CF 2 kHz); include scala media, TM, 3 OHC rows, scala tympani, BM, piezo film on TM undersurface at 30-60% coverage. Time-harmonic sweep 100 Hz – 10 kHz. Validate Phase 2 H(ω) approximation.
• Phase 4: closed-loop gain (BM amplitude with film ON vs OFF; target 40-60 dB recovery) + bifurcation check (subcritical, no spontaneous emissions — see Cochlear Amplifier as Hopf Oscillator).
• Phase 5: tonotopy preservation (Q₁₀ within 50% of WT across cochlear locations).
• Phase 6: safety + heat (Δ T <0.01 K; field ≤electroporation threshold at 90 dB).
• Phase 7: explant bench validation (film-on-glass coupons → DPOAE measurement on Holt-lab explant).

Software stack: FEniCS / FreeFEM++ (free) or COMSOL (if licensed). Python+NumPy+SciPy for the Boltzmann prestin model (V_½ = -40 mV, z = 0.8, Q_max = 3 pC per cell).

Kill criteria and go/no-go gates

Gate	Pass	Kill	Action on kill
Phase 1 (voltage budget)	V_wall ≥10 mV @ 60 dB	<5 mV	Done — conditional pass with bundle-scale geometry
Phase 2 (frequency × strain)	Audiogram passes at clinical SPLs	Beam-only → fails	Done — requires wall-curvature geometry
Phase 3 FEM (perilymph coupling)	≥30% of V_oc reaches OHC wall	<10%	Electrostatic screening kills hypothesis; pivot to insulated electrode
Phase 4 (closed-loop gain)	BM gain ≥10 dB ON vs OFF	<3 dB	Feedback insufficient; more coverage or higher d
Phase 5 (tonotopy)	Q₁₀ within 50% WT	broadband flatten	Patterned deposition / spatial gating
Phase 6 (biocompat + heat)	ΔT <0.01 K; no 6-mo degradation	overheating	PLLA biodegradable variant
Phase 7 (explant bench)	DPOAE recovery ≥10 dB vs control	<3 dB	Iterate from FEM
Phase 8 (mouse STRC-KO)	ABR improvement ≥15 dB	no change	Publishable negative

Hard stop: Phase 3 FEM failure (field cannot reach prestin across perilymph) kills the hypothesis. Phase 1/2 suggest audio-frequency AC fields survive ionic screening; FEM confirmation is gate-critical.

Why this is not a cochlear implant

A cochlear implant bypasses the entire cochlea and stimulates spiral-ganglion neurons directly — crude spatial resolution, no natural amplification, no Hopf criticality. This piezoelectric amplifier preserves natural cochlear function (BM, spiral ganglion, tonotopy, binaural processing) and only replaces the broken STRC-dependent mechanical coupler with an electrical one. A microscopic prosthesis for one molecular mechanism, not a gross sensory bypass.

Why it was never tried

• Audiologists think in sound → mechanical → neural. Piezoelectric substitution for mechanical coupling is electronic-engineering thinking, not clinical thinking.
• The cochlea is surgically delicate; the bar for implanting foreign material is high. Nanoparticles via round window (like AAV) are a lower bar with precedent (A666-PLA, gold-NP perfusion, Sci Transl Med 2024).
• Cross-field gap: piezoelectrics specialists work on MEMS and energy harvesting, not hearing.
• Piezoelectric bone-conduction implants exist but bypass the cochlea; nobody has proposed a sub-cellular piezoelectric device that works with the existing cochlear amplifier.

Resources and validation partners

Compute: Phases 1-2 complete on MacBook. Phase 3 FEM runs on 32-CPU workstation (FEniCS free) or COMSOL ($5-10 k academic license).

Materials: PVDF-TrFE powder from Piezotech (France) or MeasureSpec, $500-2k/g.RADA-16from3-DMatrixMedical,$1 k/mg. Antibody functionalisation $2-5k.Particlecharacterisation$0.5-2 k.

Wet partners:

• Jeffrey Holt — OHC explant, AFM electromotility, DPOAE. Warm from Derstroff 2026.
• Shu lab — STRC KO mouse + in-vivo audiology.
• Materials-science collaborator (TBD) for nanoparticle fabrication — MIT Nano, Harvard SEAS, ETH Zurich piezoelectric groups.
• Piezotech direct R&D partnership.

Budget: $30-70k+9-12monthstofirstin-vivodata.Mostexpensiveofthethreetopalienhypotheses($10-20 k pharmacochaperone, $6-13kC{a}^{2+}oscillation)—stillfarbelowgenetherapy($500 k-$2 M).

Risks and mitigations (condensed)

Risk	Mitigation
Electrostatic screening in perilymph	Phase 3 FEM gate-critical; AC at audio freq bypasses DC screening
Film disrupts BM tonotopy by added mass	100-nm film mass << TM; Phase 5 confirms
Disconnected-island film coverage insufficient	Each OHC needs one patch; SAP carrier improves adhesion
Biocompat in 150 mM K⁺ endolymph	PVDF-TrFE has decades of in-vivo safety; PLLA pediatric-safe first
Particle migration / aggregation	OHC-targeting ligand; re-dose 6-12 mo if needed
Overamplification → spontaneous tinnitus	Phase 4 subcritical-gain design
ABR shift from foreign material	Mouse pilot longitudinal audiometry
Regulatory path (FDA Class III)	Start with biodegradable PLLA; compassionate-use pediatric
Broadband amplification → poor speech discrimination	Patterned deposition for spatial selectivity
Cochlear implant comparison	Target moderate-loss window where CI not indicated (Misha’s regime)

Why this is the alien’s default answer

An alien species that mastered materials science before molecular biology would never think “repair a 5.3 kb gene via viral capsid.” They would think: “The problem is a broken piezo-mechanical coupler. Replace the coupler with a better one. Done in one afternoon.” Everything about this hypothesis is an engineering problem. Everything about gene therapy is a biology problem. The alien starts from engineering and arrives at a device.

Files / Models

Full phase-by-phase results in child notes:

• STRC Piezo Voltage Budget PVDF-TrFE — Phase 1 per-unit-area capacitive divider
• STRC Piezo Frequency Response Bundle Mechanics — Phase 2 strain model + audiogram sweep
• STRC Piezo Delivery Feasibility OHC Targeting — Phase 3 capture-efficiency + A666 selectivity + dose-response

Scripts + raw outputs in ~/STRC/models/:

• piezo_voltage_budget.py / _results.json / .png — Phase 1
• piezo_phase2_frequency_bundle.py / _results.json / .png — Phase 2
• piezo_phase3_delivery_feasibility.py / .json / .png — Phase 3

Connections

• [see-also] STRC Piezo Voltage Budget PVDF-TrFE — Phase 1 voltage budget
• [see-also] STRC Piezo Frequency Response Bundle Mechanics — Phase 2 frequency / audiogram
• [see-also] STRC Piezo Delivery Feasibility OHC Targeting — Phase 3 delivery kinetics
• [see-also] Prestin and OHC Electromotility — target molecule; 10 mV threshold is design constraint
• [see-also] Cochlear Amplifier as Hopf Oscillator — feedback-loop context; bifurcation-stability constraint
• [see-also] STRC Synthetic Peptide Hydrogel HTC — piezo-composite hydrogel variant
• [see-also] Jeffrey Holt — primary wet-validation partner
• [applies] Misha — therapy target